Science breadcrumb arrow Publications

Scientific Publications and Presentations

Science That Moves Neuroscience Forward

Our scientific publications reflect our commitment to advancing neuroscience through rigorous research, transparent data sharing, and ongoing collaboration with the scientific community.

Search by Keyword

Search Facet

Filter by Focus Area

Focus Area Filter
  • Vormatrigine
  • Relutrigine
  • Ulixacaltamide
  • Elsunersen
  • Other

Filter by Focus Area

Focus Area Filter Dropdown

Filter by Year

Year Filter
  • 2026
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021

Filter by Year

Year Filter - Dropdown

Filter by Meeting

Meeting Filter
  • AAN Annual Meeting
  • AES Annual Meeting
  • Behind the Seizure Scientific Exhibit
  • Drug Discovery for ION Channels XXII Meeting
  • EEC Meeting
  • IAPRD Meeting
  • IEC Meeting
  • MDS Congress
  • Oligonucleotides for CNS Meeting
  • Syngap1 Conference

Filter by Meeting

Meeting Filter - Dropdown
2026 | EEC Meeting

Elsunersen, a Novel Antisense Oligonucleotide, Shows Marked Seizure Reduction and Broad Functional Improvements Highlighting Disease-Modifying Potential in Early Onset SCN2A Developmental and Epileptic Encephalopathy: Results from the EMBRAVE Part A Study

2026 | EEC Meeting

Updates from the First-in-human Phase 1 Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Food Effect of Vormatrigine in Healthy Participants

2026 | EEC Meeting

High Seizure Burden and Limited Treatment Persistence in Epilepsy: Findings from the EMPOWER Observational Study and a US Real-World Claims Analysis

2026 | EEC Meeting

POWER1 – A Double-Blind, Randomized, Multicenter Registrational Study Evaluating the Efficacy and Safety of Vormatrigine in Adults with Focal Onset Seizures

2026 | EEC Meeting

Vormatrigine Rapidly Reduces Seizures in Adults with Treatment-Resistant Epilepsy: Results from the RADIANT Study

2026 | EEC Meeting

Vormatrigine Exhibits a Favorable Drug-Drug Interaction Profile Supporting Broad Combination Use with Antiseizure Medications

2026 | EEC Meeting

Efficacy and Safety of Relutrigine in Pediatric Participants with SCN2A- and SCN8A-Related Developmental and Epileptic Encephalopathies: Results from the EMBOLD Study

2026 | EEC Meeting

Preclinical Findings of Relutrigine, a Precision Sodium Channel Modulator, Highlight Anticonvulsant Potential Across Broad DEEs

2026 | EEC Meeting

PAC-DEE: An Extension of the Praxis Analysis of Concordance Framework for Establishing the Predictive Validity of Preclinical Seizure Models across Broad Developmental and Epileptic Encephalopathies

2026 | MDS Congress

Ulixacaltamide Demonstrates Superiority Over Placebo as Monotherapy and as Add-on to Propranolol in EssentialTremor: Phase 3 ESSENTIAL3 Study 1

Explore More

Link to: Pipeline

Pipeline

Explore our pipeline of investigational therapies targeting biologically defined mechanisms across essential tremor, DEEs, and epilepsy.

Link to: Science

Our Science

Learn how insights from genetics, neuronal excitability, and disease biology inform our approach to developing potential therapies for neurologic disorders.

Built for Possibility

Our approach is designed to build on each discovery to advance research toward new treatment options. It fuels continued innovation, persistence through challenges, and meaningful patient impact.

Patients

Pipeline

Science

Investors & Media

About

Expanded Access Policy
Terms + Conditions
Privacy Policy

© 2026 Praxis Precision Medicines, Inc.
All rights reserved.

Praxis Precision Medicines and the Praxis logo are trademarks of Praxis Precision Medicines, Inc.